Login to Your Account

Valeant Says 'Eye' to Buyout of Visudyne: $112M for QLT

By Randy Osborne
BioWorld Today Contributing Writer

Tuesday, September 25, 2012

With $112.5 million in hand from the sale of its wet, age-related macular degeneration (AMD) therapy Visudyne, QLT Inc. faced questions regarding payouts to shareholders and the fate of the company's oral retinoid program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription